Last updated: February 27, 2026
What is NDC 75907-0083?
NDC 75907-0083 refers to Tremfya (guselkumab), a monoclonal antibody approved by the FDA for the treatment of moderate to severe plaque psoriasis. It is marketed by Janssen Pharmaceuticals and is part of the IL-23 inhibitor class.
Market Overview
Market Size
The global psoriasis treatment market was valued at approximately USD 12.5 billion in 2022, with biologics accounting for around 70% of the market. Tremfya holds a significant share within the biologic segment, which is projected to grow at a CAGR of 8–10% through 2028.
Competitive Landscape
Key competitors include:
- Humira (adalimumab)
- Cimzia (certolizumab pegol)
- Stelara (ustekinumab)
- Taltz (ixekizumab)
- Cosentyx (secukinumab)
Tremfya's positioning centers on its IL-23 inhibition mechanism, which has demonstrated superior efficacy and safety profiles compared to some competitors.
Market Penetration
As of 2023, Tremfya holds an estimated 12–15% market share within biologic treatments for plaque psoriasis, with indications expanding into psoriatic arthritis and Crohn’s disease.
Price Analysis
Current Pricing
- Per-Patient Cost: Approximate wholesale acquisition cost (WAC) for Tremfya is USD 6,400 per 100 mg injection.
- Dosing Schedule: 100 mg initially, then every 8 weeks after week 16.
- Annual Cost: Estimated USD 76,800 per patient, assuming continued use.
Reimbursement Policies
Insurance coverage varies, but Tremfya is generally preferred due to its efficacy profile. Out-of-pocket costs can range from USD 50 to USD 400 per injection, depending on insurance plans.
Market Pricing Trends
- Price increases for biologics have averaged 4–6% annually over the past five years.
- Price reductions have been observed in some markets due to biosimilar entry or policy interventions, although biologics maintain high prices owing to patent protections and manufacturing costs.
Price Projections (2023–2028)
| Year |
Estimated Per-Patient Price (USD) |
Notes |
| 2023 |
6,400 |
Current WAC price |
| 2024 |
6,720 (+5%) |
Expected moderate inflation, no biosimilar impact yet |
| 2025 |
7,056 (+5%) |
Continued inflation, potential emerging biosimilar competition |
| 2026 |
7,409 (+5%) |
Biosimilar approvals might influence pricing dynamics |
| 2027 |
7,779 (+5%) |
Market stabilization expected, additional biosimilar entry risk |
| 2028 |
8,168 (+5%) |
Possible price stabilization or slight reduction if biosimilar market matures |
Note: Prices are based on historical trends and industry reports; actual pricing may vary due to policy changes, negotiations, and biosimilar development.
Regulatory and Patent Considerations
- Patent Exclusivity: Patent protection extends until at least 2028, delaying generic biosimilar entries.
- Biosimilar Development: Several biosimilars for IL-23 inhibitors are in different stages; their impact on Tremfya’s pricing could manifest starting 2029.
Key Market Drivers
- Incremental growth from expanding indications.
- Adoption in psoriatic arthritis and Crohn’s disease.
- Competitive positioning through efficacy and safety advantages.
Risks
- Biosimilar entry reducing prices.
- Regulatory changes limiting pricing flexibility.
- Market saturation or patient migration to oral therapies.
Summary
Tremfya’s global market remains stable, with pricing expected to increase annually by about 5%, barring biosimilar market entries or policy shifts. Its market share is poised for growth as indications expand and biosimilar competition remains limited through 2028.
Key Takeaways
- NDC 75907-0083 (Tremfya) is a leading IL-23 biologic for psoriasis with a significant market share.
- Current wholesale price is approximately USD 6,400 per injection, leading to annual costs near USD 77,000.
- Prices are projected to grow at about 5% annually through 2028, assuming no biosimilar competition.
- Market expansion into other immune-mediated conditions supports revenue growth.
- Biosimilar competition beginning late 2028 could influence future pricing.
FAQs
Q1: How does Tremfya’s price compare to other biologics for psoriasis?
A1: It is generally comparable, with some biologics like Humira or Cosentyx costing slightly less or more depending on dosing and insurance negotiations.
Q2: When are biosimilars for IL-23 inhibitors expected to enter the market?
A2: Biosimilars are under development, with some approvals possible by 2029, potentially affecting prices.
Q3: What factors could accelerate price decreases?
A3: Biosimilar approvals, policy reforms, or increased market competition.
Q4: Did recent clinical data impact Tremfya’s market share?
A4: Positive data contributed to increased adoption, particularly in indications beyond psoriasis.
Q5: Are there any legal barriers to biosimilar entry?
A5: No significant legal barriers are currently preventing biosimilar development, but patent protections delay early market entry.
References
[1] MarketWatch. (2023). Global psoriasis treatment market analysis.
[2] IQVIA. (2022). Biologic drug price trends.
[3] FDA. (2022). Tremfya (guselkumab) approval history.
[4] EvaluatePharma. (2023). Biosimilar pipeline and market impact projections.
